Unlocking the Potential of IFT46: A Potential Drug Target and Biomarker

Target Name: IFT46

NCBI ID: G56912

IFT46

Unlocking the Potential of IFT46: A Potential Drug Target and Biomarker

Introduction

Intraflagellar transport protein 46 (IFT46) is a protein that plays a crucial role in the transport of mitochondrial DNA in the cell nucleus. It is a member of the known IFT protein family, which also includes IFT43 and IFT45. IFT46 has been identified as a potential drug target and biomarker due to its unique structure, function, and involvement in various cellular processes.

Structure and Function

IFT46 is a 21-kDa protein that consists of 205 amino acid residues. It has a unique 21-amino acid residue at its N-terminus, which is unusual for a protein of its size. The protein has a linear molecular structure with a single transmembrane region and a cytoplasmic tail.

IFT46 functions as a mitochondrial protein by transporting DNA into the cytoplasm in a process called mitochondrial import. This process is critical for the proper functioning of mitochondria, as DNA is responsible for the production of the cell's energy. The import of DNA into the cytoplasm is a highly regulated process, and IFT46 is involved in this process by using a unique mechanism to ensure the proper delivery of the protein.

IFT46 has been shown to play a crucial role in various cellular processes, including cell growth, apoptosis, and metabolism. For example, studies have shown that IFT46 is involved in the regulation of cell growth and the response to stress in cancer cells. It has has also been shown to play a role in the regulation of apoptosis, which is the process by which cells undergo programmed cell death.

IFT46 has also been shown to be involved in the regulation of metabolism, including the metabolism of fatty acids. Studies have shown that IFT46 is a key protein in the transport of fatty acids into the mitochondria, where they can be used for energy production.

Drug Target Potential

IFT46's unique structure and function make it an attractive drug target. Due to its involvement in various cellular processes, IFT46 has been identified as a potential drug target for various diseases, including cancer, metabolism-related diseases, and neurodegenerative diseases.

One of the main advantages of IFT46 as a drug target is its makingness. IFT46 is a protein that is expressed in all cell types, making it a potential target for small molecules that can be used to inhibit its function without affecting the function of other proteins.

Another advantage of IFT46 is its specificity. IFT46 is expressed in high levels in cancer cells, making it an attractive target for anti-cancer drugs. Studies have shown that IFT46 can be downregulated in cancer cells, which could make them more sensitive to anti-cancer drugs. cancer drugs.

IFT46's role in the regulation of cell apoptosis also makes it a potential target for drugs that can induce or enhance apoptosis in cancer cells.

Biomarker Potential

IFT46 has also been identified as a potential biomarker for various diseases. Its unique structure and function make it an attractive target for diagnostic tools that can detect changes in the expression or activity of IFT46.

IFT46 has been shown to be involved in the regulation of cell growth, apoptosis, and metabolism, which are all potential biomarkers for various diseases. For example, IFT46 has been shown to be involved in the regulation of

Protein Name: Intraflagellar Transport 46

Functions: Forms part of a complex involved in intraflagellar transport (IFT), the bi-directional movement of particles required for the assembly, maintenance and functioning of primary cilia. May play a role in chondrocyte maturation and skeletogenesis (By similarity)

The "IFT46 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IFT46 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets